Intech Investment Management LLC Invests $3.27 Million in Qiagen N.V. $QGEN

Intech Investment Management LLC acquired a new position in Qiagen N.V. (NYSE:QGEN) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 73,813 shares of the company’s stock, valued at approximately $3,270,000.

Several other hedge funds also recently added to or reduced their stakes in the business. United Services Automobile Association acquired a new stake in Qiagen in the first quarter worth about $239,000. Envestnet Asset Management Inc. boosted its stake in Qiagen by 26.6% in the 2nd quarter. Envestnet Asset Management Inc. now owns 425,396 shares of the company’s stock worth $20,439,000 after purchasing an additional 89,301 shares in the last quarter. Atria Investments Inc boosted its stake in Qiagen by 2.9% in the 2nd quarter. Atria Investments Inc now owns 7,674 shares of the company’s stock worth $369,000 after purchasing an additional 218 shares in the last quarter. Amalgamated Bank grew its position in Qiagen by 1.8% during the 2nd quarter. Amalgamated Bank now owns 11,751 shares of the company’s stock worth $565,000 after purchasing an additional 209 shares during the last quarter. Finally, Simon Quick Advisors LLC acquired a new position in Qiagen during the 2nd quarter valued at approximately $208,000. 70.00% of the stock is owned by institutional investors and hedge funds.

Qiagen Stock Performance

Shares of QGEN stock opened at $48.83 on Tuesday. Qiagen N.V. has a 52-week low of $39.61 and a 52-week high of $57.81. The company has a quick ratio of 3.31, a current ratio of 3.90 and a debt-to-equity ratio of 0.44. The stock has a market cap of $10.31 billion, a PE ratio of 24.22, a price-to-earnings-growth ratio of 2.43 and a beta of 0.70. The business has a 50-day simple moving average of $50.01 and a 200-day simple moving average of $49.32.

Qiagen (NYSE:QGEN) last announced its quarterly earnings results on Thursday, February 5th. The company reported $0.62 earnings per share for the quarter, beating the consensus estimate of $0.61 by $0.01. Qiagen had a return on equity of 14.56% and a net margin of 20.33%.The company had revenue of $540.42 million during the quarter, compared to analysts’ expectations of $528.53 million. During the same period last year, the business earned $0.61 earnings per share. Qiagen’s quarterly revenue was up 3.6% on a year-over-year basis. On average, equities analysts expect that Qiagen N.V. will post 2.26 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on QGEN shares. Weiss Ratings reissued a “hold (c)” rating on shares of Qiagen in a report on Monday, December 29th. Robert W. Baird set a $53.00 price target on Qiagen in a research note on Friday, February 6th. TD Cowen reissued a “hold” rating on shares of Qiagen in a report on Friday, February 6th. JPMorgan Chase & Co. lifted their target price on Qiagen from $55.00 to $60.00 and gave the stock an “overweight” rating in a report on Friday, February 6th. Finally, UBS Group set a $52.00 target price on Qiagen in a research report on Monday, February 9th. Four investment analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Qiagen has a consensus rating of “Hold” and a consensus target price of $55.20.

Qiagen Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.